Aurobindo Pharma receives USFDA approval for Zidovudine, Lamivudine & Zidovudine Tablets

Aurobindo Pharma has received the final approval for Zidovudine Tablets 60 mg and Lamivudine and Zidovudine Tablets 30mg / 60mg from US Food and Drug Administration (USFDA).

Both these new drug applications are for pediatric strengths and are developed based on United Nations initiative to develop pediatric formulations. The products are indicated for the treatment of NIV-infection in combination with other antiretrovirals (ARVs).

Aurobindo now has a total of 98 ANDA approvals (70 final approvals and 28 tentative approvals) from USFDA, which include 30 products in the ARV segment (8 final approvals and 22 tentative approvals).